Paediatric pulmonary hypertension: Monitoring progress and identifying unmet needs

European Respiratory Review

Volumn 18, Issue 111, 2009, Pages 18-23

  Beghetti, M ^a  

^a Hopital des Enfants Hopitaux universitaires de Geneve   (Switzerland)

Author keywords

Drug therapy; Epidemiology; Paediatric; Pulmonary hypertension; Registries; Review

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ILOPROST; NITRIC OXIDE; PROSTACYCLIN; PROSTANOID; SILDENAFIL; UNIPROST;

ALGORITHM; AORTOPULMONARY SHUNT; ARTICLE; CHILD; CHILDHOOD DISEASE; CONGENITAL HEART DISEASE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DRUG SAFETY; HEART CATHETERIZATION; HEART LUNG TRANSPLANTATION; HEART SURGERY; HUMAN; LUNG TRANSPLANTATION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PULMONARY HYPERTENSION; REGISTER;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; HUMANS; HYPERTENSION, PULMONARY;

EID: 61649107920     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00011109     Document Type: Article

References (49)

1. Widlitz A, Barst RJ. Pulmonary arterial hypertension in children. Eur Respir J 2003; 21: 155-176.
2. Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 697-704.
3. Beghetti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res 2008; 64: 200-204.
4. Fasnacht MS, Tolsa JF, Beghetti M. The Swiss registry for pulmonary arterial hypertension: the paediatric experience. Swiss Med Wkly 2007; 137: 510-513.
5. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart 2008; [Epub ahead of print PMID: 18952635].
6. Stricker H, Domenighetti G, Popov W, et al. Severe pulmonary hypertension: data from the Swiss Registry. Swiss Med Wkly 2001; 131: 346-350.
7. Fraisse A, Godart F, Bonnet DVG, et al. The French registry of pulmonary hypertension in children: rationale and design. Curr Med Res Opin 2007; 23: Suppl. 2, S27-S33.
8. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 5S-12S.
9. Beghetti M, Berger RM, Schulze-Neick I, Barst R, Humpl T, Raskob G. TOPP: the first international registry in pediatric pulmonary hypertension. Eur Respir J 2008; 32: Suppl. 52, 169s-170s.
10. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131: 1917-1928.
11. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243-2278.
12. Rashid A, Ivy D. Severe paediatric pulmonary hypertension: new management strategies. Arch Dis Child 2005; 90: 92-98.
13. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197-1208.
14. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
15. Sandoval J, Bauerle O, Gomez A, Palomar A, Martinez Guerra ML, Furuya ME. Primary pulmonary hypertension in children: clinical characterization and survival. J Am Coll Cardiol 1995; 25: 466-474.
16. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110: 660-665.
17. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804.
18. Haworth SG. The management of pulmonary hypertension in children. Arch Dis Child 2008; 93: 620-625.
19. Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. JAmCollCardiol2008; 51: 161-169.
20. Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73: 372-382.
21. Gilbert N, Luther YC, Miera O, et al. Initial experience with bosentan (Tracleer) as treatment for pulmonary arterial hypertension (PAH) due to congenital heart disease in infants and young children. Z Kardiol 2005; 94: 570-574.
22. Ivy DD, Doran A, Claussen L, Bingaman D, Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol 2004; 93: 943-946.
23. Krishnan U, Krishnan S, Gewitz M. Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies. Pediatr Cardiol 2008; 29: 1082-1086.
24. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart 2006; 92: 664-670.
25. van Loon RL, Hoendermis ES, Duffels MG, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J 2007; 154: 776-782.
26. Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005; 111: 3274-3280.
27. Micheletti A, Hislop AA, Lammers A, et al. Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension. Heart 2006; 92: 969-972.
28. Blanc J, Vouhe P, Bonnet D. Potts shunt in patients with pulmonary hypertension. N Engl J Med 2004; 350: 623.
29. The International Society for Heart and Lung Transplantation. ISHLT Transplant Registry Quarterly Reports for Lung in Europe. Based on data as of August 1, 2008. https://www.ishlt.org/registries/quarterlyDataReportResults.asp? organ=LU&rptType=recip-p-surv&continent=3 Date last accessed: December 15, 2008. Based on UNOS/ISHLT data as of August 1, 2008.
30. Kawut SM, Palevsky HI. New answers raise new questions in pulmonary arterial hypertension. Eur Respir J 2004; 23:799-801.
31. Kawut SM, Palevsky HI. Surrogate end points for pulmonary arterial hypertension. Am Heart J 2004; 148:559-565.
32. Peacock A, Naeije R, Galie N, Reeves JT. End points in pulmonary arterial hypertension: the way forward. Eur Respir J 2004; 23: 947-953.
33. Roberts K, Preston I, Hill NS. Pulmonary hypertension trials: current end points are flawed, but what are the alternatives? Chest 2006; 130: 934-936.
34. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
35. McKenna SP, Doughty N, Meads DM, Doward LC, Pepke- Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006; 15: 103-115.
36. Taichman D, Zlupko M, Harhay M, et al. Evaluation of disease-specific health-related quality of life in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 177: A918.
37. Taichman DB, Shin J, Hud L, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 2005; 6: 92.
38. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870.
39. McLure LER, Peacock AJ. Imaging of the heart in pulmonary hypertension. Int J Clin Pract 2007; 61: 15-26.
40. Sallach SM, Peshock RM, Reimold S. Noninvasive cardiac imaging in pulmonary hypertension. Cardiol Rev 2007; 15:97-101.
41. Sciomer S, Magri D, Badagliacca R. Non-invasive assessment of pulmonary hypertension: Doppler-echocardio-graphy. Pulm Pharmacol Ther 2007; 20: 135-140.
42. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161: 487-492.
43. Lammers AE, Hislop AA, Flynn Y, Haworth SG. The 6- minute walk test: normal values for children of 4-11 years of age. Arch Dis Child 2008; 93: 464-468.
44. Geiger R, Strasak A, Treml B, et al. Six-minute walk test in children and adolescents. J Pediatr 2007; 150: 395-399.
45. Li AM, Yin J, Au JT, et al. Standard reference for the six- minute-walk test in healthy children aged 7 to 16 years. Am J Respir Crit Care Med 2007; 176: 174-180.
46. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48: 2546-2552.
47. Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. Int J Cardiol 2008; [Epub ahead of print PMID: 18599134].
48. Van Albada ME, Loot FG, Fokkema R, Roofthooft MT, Berger RM. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res 2008; 63: 321-327.
49. Bernus A, Wagner BD, Accurso F, Doran A, Kaess H, Ivy DD. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest 2008; [Epub ahead of print PMID: 18849405].